Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:EC 2.1.1.354 ([histone H3]-lysine(4) N-trimethyltransferase) inhibitor
go back to main search page
Accession:CHEBI:228263 term browser browse the term
Definition:An EC 2.1.1.* (methyltransferases) inhibitor that interferes with the action of [histone H3]-lysine(4) N-trimethyltransferase (EC 2.1.1.354).
Synonyms:related_synonym: ASH1L inhibitor;   ASH1L inhibitors;   EC 2.1.1.354 ([histone H3]-lysine(4) N-trimethyltransferase) inhibitors;   EC 2.1.1.354 inhibitor;   EC 2.1.1.354 inhibitors;   KMT2H inhibitor;   KMT2H inhibitors;   KMT3C inhibitor;   KMT3C inhibitors;   KMT3D inhibitor;   KMT3D inhibitors;   KMT3E inhibitor;   KMT3E inhibitors;   MLL5 inhibitor;   MLL5 inhibitors;   PRDM9 inhibitor;   PRDM9 inhibitors;   SMYD1 inhibitor;   SMYD1 inhibitors;   SMYD2 inhibitor;   SMYD2 inhibitors;   SMYD3 inhibitor;   SMYD3 inhibitors;   [histone H3]-lysine(4) N-trimethyltransferase inhibitor;   [histone H3]-lysine(4) N-trimethyltransferase inhibitors



show annotations for term's descendants           Sort by:
LLY-507 term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Cd36 CD36 molecule multiple interactions ISO [LLY-507 affects the susceptibility to [Lipopolysaccharides co-treated with IFNG protein]] which results in decreased expression of CD36 mRNA CTD PMID:29718165 NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903
JBrowse link
G Ifng interferon gamma multiple interactions ISO [LLY-507 affects the susceptibility to [Lipopolysaccharides co-treated with IFNG protein]] which results in decreased expression of CD36 mRNA; [LLY-507 affects the susceptibility to [Lipopolysaccharides co-treated with IFNG protein]] which results in decreased expression of MARCO mRNA; [LLY-507 affects the susceptibility to [Lipopolysaccharides co-treated with IFNG protein]] which results in decreased expression of MMP9 mRNA; [LLY-507 affects the susceptibility to [Lipopolysaccharides co-treated with IFNG protein]] which results in decreased expression of MSR1 mRNA; [LLY-507 affects the susceptibility to [Lipopolysaccharides co-treated with IFNG protein]] which results in increased expression of IL6 mRNA; [LLY-507 affects the susceptibility to [Lipopolysaccharides co-treated with IFNG protein]] which results in increased expression of TNF mRNA CTD PMID:29718165 NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
JBrowse link
G Il6 interleukin 6 multiple interactions ISO [LLY-507 affects the susceptibility to [Lipopolysaccharides co-treated with IFNG protein]] which results in increased expression of IL6 mRNA CTD PMID:29718165 NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
JBrowse link
G Marco macrophage receptor with collagenous structure multiple interactions ISO [LLY-507 affects the susceptibility to [Lipopolysaccharides co-treated with IFNG protein]] which results in decreased expression of MARCO mRNA CTD PMID:29718165 NCBI chr13:31,616,278...31,648,521
Ensembl chr13:31,616,278...31,648,521
JBrowse link
G Mmp9 matrix metallopeptidase 9 multiple interactions ISO [LLY-507 affects the susceptibility to [Lipopolysaccharides co-treated with IFNG protein]] which results in decreased expression of MMP9 mRNA CTD PMID:29718165 NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
JBrowse link
G Msr1 macrophage scavenger receptor 1 multiple interactions ISO [LLY-507 affects the susceptibility to [Lipopolysaccharides co-treated with IFNG protein]] which results in decreased expression of MSR1 mRNA CTD PMID:29718165 NCBI chr16:52,717,775...52,803,602
Ensembl chr16:52,717,732...52,799,676
JBrowse link
G Smyd2 SET and MYND domain containing 2 multiple interactions ISO LLY-507 binds to and results in decreased activity of SMYD2 protein CTD PMID:25825497 NCBI chr13:101,425,270...101,466,576
Ensembl chr13:101,425,273...101,466,576
JBrowse link
G Tnf tumor necrosis factor multiple interactions ISO [LLY-507 affects the susceptibility to [Lipopolysaccharides co-treated with IFNG protein]] which results in increased expression of TNF mRNA CTD PMID:29718165 NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
JBrowse link

Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 19808
    role 19784
      biological role 19782
        biochemical role 19496
          enzyme inhibitor 18704
            EC 2.* (transferase) inhibitor 14863
              EC 2.1.* (C1-transferase) inhibitor 3508
                EC 2.1.1.* (methyltransferases) inhibitor 684
                  EC 2.1.1.354 ([histone H3]-lysine(4) N-trimethyltransferase) inhibitor 8
                    AZ505 0
                    LLY-507 8
paths to the root